Today in Peak History (April 11-April 20)
Release time:
2020-08-14
peak (4# March 11 - 4# July 20 )
1987 4 , due to the outstanding achievements of peak in horizontal alliance, formation of enterprise groups and rapid development, reporters from Xinhua News Agency, Central People's Broadcasting Station, China Daily, China Youth Daily, China Education News, Guangming Daily in Zhejiang Branch, etc., went to Jinhua Cement Plant for joint interviews. ◆ 1988
4 May 12 , Wucheng Branch of Jianfeng Cement Group was successfully put into trial production. ◆ 1994
4 April 19 , Du Zihong, then chairman and general manager of Jianfeng Group, was named the fifth national outstanding entrepreneur and won the Golden Globe Award, the highest award for Chinese entrepreneurs. ◆ 1998
4 14 , a feature film reporting the successful experience of Jianfeng Group's "diversified development" was broadcast on CCTV's "Business Way" column. ◆ 1998
4 February 17 , as one of the strategic measures for enterprises to cultivate cross-century "heavy" talents and create conditions for industrial upgrading and enterprise expansion, Jianfeng Group, Southwest Normal University and Hangzhou University jointly organized the postgraduate course of business administration. This is also the first time that enterprises and universities in Zhejiang Province have jointly held postgraduate degree training, which has been praised by the leaders of Jinhua City as "supporting the government to implement the strategy of revitalizing the city through science and education". ◆ 2000
4 January 10 , Jianfeng Pharmaceutical Jinqiao Chemical Co., Ltd. was officially put into production. ◆ 2001
4 11 , gatifloxacin, the first national class I new drug developed by Jianfeng Pharmaceutical, completed clinical trials and held a clinical trial summary meeting in Nanjing. ◆ 2005
4 September 13 , the "Class I New Drug Gatifloxacin and Its Preparations" project won the first prize of municipal scientific and technological progress. On the same day, Jianfeng Group was awarded the "Jinhua Manufacturing Information Application Project Demonstration Enterprise". ◆ 2007
4 August 16 , Jianfeng Group's board of directors deliberated and approved the cooperation proposal between Jianfeng Group and China Building Materials Group and its subsidiaries. On the same day, Jianfeng Group signed a cooperation framework agreement with China Construction Group and an investment agreement with its subsidiary China Building Materials. This marks the official start of the project of Jianfeng Group, China Construction Group and China Building Materials to cooperate in the construction of cement projects. (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page